Related Experiment Video
Updated: May 4, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Updated treatment algorithm of pulmonary arterial hypertension
Nazzareno Galiè1, Paul A Corris2, Adaani Frost3
1Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy.
This study revises the pulmonary arterial hypertension (PAH) treatment algorithm, incorporating new evidence to simplify and update recommendations for physicians and patients. It aims to provide a comprehensive yet accessible guide for managing PAH effectively.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Pulmonary arterial hypertension (PAH) treatment algorithms face conflicting demands for comprehensiveness and simplicity.
- Algorithms integrate diverse recommendations (clinical, hemodynamic, pharmacological) with varying evidence levels.
- Multiple stakeholders with different needs utilize PAH treatment algorithms.
Purpose of the Study:
- To update the current evidence-based PAH treatment algorithm.
- To address challenges in algorithm development and stakeholder needs.
- To propose revisions based on new scientific information.
Main Methods:
- Revisiting three main areas of the current PAH treatment algorithm: general measures, initial therapy, and response to therapy.
- Highlighting new information from the past five years.
- Adopting European Society of Cardiology (ESC) grades of recommendation and levels of evidence.
Main Results:
- New information from the last five years will be integrated into the algorithm.
- Proposed updates will be presented for each section of the algorithm.
- Treatments will be ranked using ESC guidelines for recommendations and evidence levels.
Conclusions:
- The updated algorithm aims to be comprehensive, informative, simple, and straightforward.
- Proposed revisions will enhance the evidence-based management of PAH.
- The updated algorithm will better serve diverse stakeholder needs in PAH treatment.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

